Recent research have centered on the intersection of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GIP activators are widely employed for addressing type 2 diabetes, their potential consequences on motivation circuits, specifically mediated by d